The Geneva University Hospitals, the University of Geneva and their spin-off Endotelix have created the best possible target molecule for the antibodies responsible for antiphospholipid syndrome.
Each year, around two of every 100,000 American adults receive a new diagnosis of antiphospholipid syndrome, or APS, an autoimmune disease known to cause inflammation and recurring, potentially fatal, blood clots.
The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sjögren syndrome, lupus, antiphospholipid syndrome, and other diseases.